[Model of platelet activation as experimental test system for screening kappa-opioid receptor ligands].
A new model is proposed for in vitro testing the efficiency of new chemical substances with kappa-opioid receptor agonist ligand properties.
A A
AA
Spasov
O Iu
OIu
Grechko
V A
VA
Anisimova
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology*; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism*; D002077:Butorphanol / Q000494:pharmacology; D057166:High-Throughput Screening Assays; D008024:Ligands; D008027:Light; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D015539:Platelet Activation / Q000187:drug effects*; D011817:Rabbits; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D012542:Scattering, Radiation
C499148:17,17'-bis(cyclopropylmethyl)-6,6',7,7'-tetrahydro-4,5-4',5'-diepoxy-6,6'-(benzylimino)(7,7'-bimorphinan)-3,3',14,14'-tetrol; D018712:Analgesics, Non-Narcotic; D001562:Benzimidazoles; D008024:Ligands; D017473:Receptors, Opioid, kappa; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D002077:Butorphanol